Komori
Occurring Fact4883Modalis Therapeutics CorporationPharmaceuticals

Notice Concerning the Recognition of Non-operating Income (Foreign Exchange Gains)

During the cumulative third-quarter period of the fiscal year ending December 2026, the company recorded ¥5 million in foreign exchange gains as non-operating income due to fluctuations in foreign exchange rates. These gains arose mainly from foreign-currency-denominated assets and liabilities held by the group.

Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
5
¥ million
Wording
Conditional
How definitive the wording is.

Recognition of Non-Operating Income (Foreign Exchange Gain)

Subject Entity

The group

Target Locations / Products

Foreign-currency-denominated assets and liabilities held by the group

OccurrenceThe cumulative third-quarter period of the fiscal year ending December 2026, from 1 January 2026 to 30 September 2026 (individual occurrence date: Not disclosed)
This disclosure11/12/2026
Cause

Foreign-Exchange Rate Fluctuations

Amount of Impact on Business Performance

Foreign exchange gains of ¥5 million (non-operating income)

Accounting period in which recognized

Cumulative third-quarter period of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026)

Outlook

This amount will fluctuate depending on future foreign exchange rate conditions.

Event that occurred
ItemDetails
Event nameRecognition of Non-Operating Income (Foreign Exchange Gain)
Date of occurrenceThe cumulative third-quarter period of the fiscal year ending December 2026, from 1 January 2026 to 30 September 2026 (individual occurrence date: Not disclosed)
Subject EntityThe group
Target Locations / ProductsForeign-currency-denominated assets and liabilities held by the group
CauseForeign-Exchange Rate Fluctuations
Amount of Impact on Business PerformanceForeign exchange gains of ¥5 million (non-operating income)
Accounting period in which recognizedCumulative third-quarter period of the fiscal year ending December 2026 (1 January 2026 to 30 September 2026)
OutlookThis amount will fluctuate depending on future foreign exchange rate conditions.
Items this document does not state (17)
Date recognized / date notice receivedImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Foreign exchange gains arose on the foreign-currency-denominated assets and liabilities held by the group due to fluctuations in foreign exchange rates.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Recognition of Non-operating Income (Foreign Exchange Gains) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori